1. American Urology Association. American Urological Association guideline: Management of benign prostatic hyperplasia (BPH). https://www.auanet.org/education/guidelines/benign-prostatic-hyperplasia.cfm. Accessed August 1, 2016.
2. Instituto de Evaluación Tecnológica en Salud. Manual metodológico para la elaboración de evaluaciones económicas en salud. http://www.iets.org.co/Manuales/Manuales/Manual%20evaluacio%CC%81n%20econo%CC%81mica%20web%2030%20sep.pdf. Accessed August 1, 2016.
3. Tufts Medical Center. Cost Effectiveness Analysis Registry. http://healtheconomics.tuftsmedicalcenter.org/cear4/. Accessed August 4, 2016.
4. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia;McConnell;N Engl J Med,2003
5. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study;Roehrborn;Eur Urol,2010